海外の治験の状況「前立腺癌」での検索結果
161件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Recruiting
- An Open-label, Single-arm, Rater-blinded, Multicenter Phase 1/2 Study to Assess Safety and Diagnostic Accuracy and Radiotherapeutic Implications of Pre-operative Ga-68-PSMA-11 PET/CT Imaging in Comparison to Histopathology, in Newly-diagnosed Prostate Cancer (PCA) Patients at High Risk for Metastasis, Scheduled for Radical Prostatectomy (RP) With Extended Pelvic Lymph Node Dissection (EPLND)
- High-risk Prostate Cancer # Prostate Cancer Metastatic # Lymphnode Metastasis;C61 - Malignant neoplasm of prostate
- Austria, Germany
- 2018-02-06
Not Recruiting
- A study of patients with prostate cancer who have previously been treated with docetaxel-based chemotherapy, where patients receive either study drug or placebo
- Patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy MedDRA version: 14.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belgium, Canada, Chile, France, Germany, Italy, Netherlands, Poland, South Africa, Spain, United Kingdom, United States
- 2009-09-03
Recruiting
- Evaluating the Utility of a Patient Decision Aid for Prospective Participants in the Trans-Tasman Radiation Oncology Group Radiotherapy - Adjuvant Versus Early Salvage Prostate Cancer Trial
- Decision-making for clinical trial participation in men with prostate cancer who have positive margins and/or pathologic stage T3 (pT3; cancer extending beyond the capsule of the prostate gland) disease following radical prostatectomy, aged over 18 years.
- Australia, New Zealand, Outside
- 2011-09-26
- PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TASQUINIMOD IN MEN WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Estonia, France, Germany, Greece, India, Israel, Italy, Korea North, Lebano, Lithuania, Mexico, Netherlands, New Zealand, Panama, Poland, Romania, Russian Federation, Slovakia, Spain, Switzerland, Taiwan, Turkey, Ukraine, United Kindgdom, United States
- 2011-08-24
Not recruiting
- The effects of cranberry capsules on cystitis in men treated with radiation for prostate cancer
- Acute non-infectious radiation cystitis;Prostate Cancer
- ,Outside, New Zealand
- 2011-08-19
Authorised
- A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- High-risk, non-metastatic castration-resistant prostate cancer (MedDRA: hormonerefractory prostate cancer) br>MedDRA version: 20.0 Level: LLT Classification code 10066489 Term: Progression of prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Peru, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2014-06-05
Not Recruiting
- A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who are responsive to such therapy - ICELAND Study
- Histologically or cytologically confirmed adenocarcinoma of the prostate (PCa) meeting the following criteria: - Locally adv. (stage T3 or T4) PCa, N0 or N+, M0 with PSA >= 5 ng/ml, or - Relapsing PCa following radical prostatectomy for clinically localized PCa with a serum PSA of >= 0.4 ng/ml or, - Relapsing PCa following radiotherapy with a serum PSA of >= 1 ng/ml as compared to a previous reference value. MedDRA version: 8.0 Level: LLT Classification code 10060862
- Austria, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Ireland, Italy, Portugal, Spain, Sweden, United Kingdom
- 2005-12-05
Not recruiting
- Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate
- Prostate Cancer
- Austria, Belgium, Denmark, France, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
- 2004-06-10
Not Recruiting
- A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Mexico, Netherlands, Peru, Poland, Puerto Rico, Romania, Russian Federation, Spain, United Kingdom, United States
- 2015-11-12
Not Recruiting
- A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, India, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Serbia, Singapore, South Africa, Sweden, Switzerland, Taiwan, Province of China, United Kingdom, United States
- 2015-11-11